Patents by Inventor Winston S. Marshall

Winston S. Marshall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Angiotensin II antagonists
    Patent number: 5693633
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5612360
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: March 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5571925
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: November 5, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5569768
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5563278
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonist intermediates
    Patent number: 5556981
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 17, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghaven Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5484780
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: January 16, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Kenneth L. Hauser, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Kumiko Takeuchi, K. Jeff Thrasher, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5401851
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: March 28, 1995
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Kenneth L. Hauser, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Kumiko Takeuchi, K. Jeff Thrasher, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5312936
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: May 17, 1994
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonist 1,3-imidazoles and use thereas
    Patent number: 5073566
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: December 17, 1991
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Disubstituted tetrazoles and their use as leukotriene antagonists
    Patent number: 4820722
    Abstract: The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 and E.sub.4 in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive amounts of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof.
    Type: Grant
    Filed: August 14, 1987
    Date of Patent: April 11, 1989
    Assignee: Eli Lilly and Company
    Inventors: F. Patrick Carr, Robert D. Dillard, Winston S. Marshall, Doris E. McCullough
  • Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
    Patent number: 4820723
    Abstract: The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive release or production of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof. Such conditions include an immediate hypersensitivity reaction of the type represented by asthma, or by shock or other adverse cardiovascular effects.
    Type: Grant
    Filed: August 14, 1987
    Date of Patent: April 11, 1989
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, Sandra K. Sigmund, Celia A. Whitesitt
  • Process for leukotriene antagonists
    Patent number: 4777299
    Abstract: 1,3-Dialkylbenzenes are acylated and deprotected in a mixture of acetic or propionic acid and hydrobromic acid. The dihydroxyphenones thus produced are intermediates in the synthesis of leukotriene antagonists.
    Type: Grant
    Filed: January 11, 1988
    Date of Patent: October 11, 1988
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, Sandra K. Sigmund, Celia A. Whitesitt
  • Process for intermediates to leukotriene antagonists
    Patent number: 4777298
    Abstract: Resorcinol is acylated in a mixture of acetic or propionic acid and hydrobromic acid. The dihydroxy acylbenzenes thus produced are intermediates in the synthesis of leukotriene antagonists.
    Type: Grant
    Filed: January 11, 1988
    Date of Patent: October 11, 1988
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, Sandra K. Sigmund, Celia A. Whitesitt
  • Cyano and thiocyano intermediates
    Patent number: 4769482
    Abstract: This invention provides novel alkane derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: September 6, 1988
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, John P. Verge
  • Tetrazole substituted compounds and their anti-allergic use
    Patent number: 4740514
    Abstract: There are described compounds of the formula ##STR1## in which R.sup.1 is hydrogen or C.sub.1-6 alkyl, R.sup.2 is hydrogen, C.sub.1-6 alkyl or C.sub.3-6 alkenyl, X and Y are each oxygen, sulphur, sulphinyl or sulphonyl, n is 2 to 6 and Z is 1H-tetrazol-5-yl, 1H-tetrazol-5-ylthio, 1H-tetrazol-5-ylsulphinyl, 1H-tetrazol-5-ylsulphonyl, cyano or thiocyano, provided that when both X and Y are oxygen Z is 1H-tetrazol-5-ylthio, 1H-tetrazol-5-ylsulphinyl, 1H-tetrazol-5-ylsulphonyl or thiocyano; and salts thereof. The compounds in which Z is other than cyano or thiocyano have pharmaceutical activity and inhibit leukotriene action or formation.
    Type: Grant
    Filed: May 27, 1986
    Date of Patent: April 26, 1988
    Assignee: Lilly Industries Limited
    Inventors: John Goldsworthy, Winston S. Marshall, John P. Verge
  • Leukotriene antagonists
    Patent number: 4661505
    Abstract: This invention provides novel alkane derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: November 3, 1982
    Date of Patent: April 28, 1987
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, John P. Verge
  • Benzonitrile and benzothiocyano intermediates
    Patent number: 4595540
    Abstract: There are described compounds of the formula ##STR1## in which R.sup.1 is hydrogen or C.sub.1-6 alkyl, R.sup.2 is hydrogen, C.sub.1-6 alkyl or C.sub.3-6 alkenyl, X and Y are each oxygen, sulphur, sulphinyl or sulphonyl, n is 2 to 6 and Z is 1H-tetrazol-5-yl, 1H-tetrazol-5-ylthio, 1H-tetrazol-5-ylsulphinyl, 1H-tetrazol-5-ylsulphonyl, cyano or thiocyano, provided that when both X and Y are oxygen Z is 1H-tetrazol-5-ylthio, 1H-tetrazol-5-ylsulphinyl, 1H-tetrazol-5-ylsulphonyl or thiocyano; and salts thereof. The compounds in which Z is other than cyano or thiocyano have pharmaceutical activity and inhibit leukotriene action or formation.
    Type: Grant
    Filed: October 19, 1983
    Date of Patent: June 17, 1986
    Assignee: Lilly Industries Limited
    Inventors: John Goldsworthy, Winston S. Marshall, John P. Verge
  • Quinoline quinones and anti-asthmatic use thereof
    Patent number: 4492704
    Abstract: This invention relates to a class of quinoline quinones, which are useful for the therapy of immediate hypersensitivity reactions, such as asthma, and in treating any condition characterized by excessive release of leukotrienes. This invention also includes a method for treating these conditions, which comprises administering to animals, including humans, an effective dose of the quinoline quinone compounds. A further part of this invention is pharmaceutical formulations containing these pharmacologically-active compounds.
    Type: Grant
    Filed: September 30, 1982
    Date of Patent: January 8, 1985
    Assignee: Eli Lilly and Company
    Inventors: Jerome H. Fleisch, Winston S. Marshall, George J. Cullinan
  • Quinoxalinedione leukotriene release inhibitors
    Patent number: 4486432
    Abstract: This invention provides for novel quinoxalinedione derivatives, the use of quinoxalinedione derivatives in treating animals suffering from immediate hypersensitivity reactions and conditions characterized by excessive release of leukotrienes, and formulations of the quinoxalinedione derivatives.
    Type: Grant
    Filed: September 30, 1982
    Date of Patent: December 4, 1984
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, Jerome H. Fleisch, George J. Cullinan